Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey

Basit Öğe Kaydı
dc.authorscopusid57348563500
dc.authorscopusid7801655696
dc.authorscopusid41661945200
dc.authorscopusid55941135700
dc.authorscopusid57200631980
dc.authorscopusid6603548937
dc.authorscopusid57220921063
dc.contributor.authorÜnal, Ç.
dc.contributor.authorÖzmen, T.
dc.contributor.authorOrdu, Ç.
dc.contributor.authorPilanci, K.N.
dc.contributor.authorİlgün, A.S.
dc.contributor.authorGökmen, E.
dc.contributor.authorAlmuradova, E.
dc.date.accessioned2024-08-25T18:51:09Z
dc.date.available2024-08-25T18:51:09Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive, HER-2 receptor-negative breast cancer. This study aimed to evaluate survival and its correlation with ODx-RS in pT1-2, N0-N1mic patients treated with adjuvant therapy based on tumor board decisions. Patients and methods: Estrogen-positive HER-2 negative early-stage breast cancer patients (pT1-2 N0, N1mic) with known ODx-RS, operated on between 2010 and 2014, were included in this study. The primary aim was to evaluate 5-year disease-free survival (DFS) rates according to ODX-RS. Results: A total of 203 eligible patients were included in the study, with a median age of 48 (range 26-75) and median follow-up of 84 (range 23-138) months. ROC curve analysis for all patients revealed a recurrence cut-off age of 45 years, prompting evaluation by grouping patients as ?45 years vs. >45 years. No significant difference in five-year DFS rates was observed between the endocrine-only (ET) and chemo-endocrine (CE) groups. However, among the ET group, DFS was higher in patients over 45 years compared to those aged ?45 years. When stratifying by ODx-RS as 0-17 and ?18, DFS was significantly higher in the former group within the ET group. However, such differences were not seen in the CE group. In the ET group, an ODx-RS ?18 and menopausal status were identified as independent factors affecting survival, with only an ODx-RS ?18 impacting DFS in patients aged ?45 years. The ROC curve analysis for this subgroup found the ODx-RS cut-off to be 18. Conclusion: This first multicenter Oncotype Dx survival analysis in Turkey demonstrates the importance of Oncotype Dx recurrence score and age in determining treatment strategies for early-stage breast cancer patients. As a different aproach to the literature, our findings suggest that the addition of chemotherapy to endocrine therapy in young patients (?45 years) with Oncotype Dx recurrence scores of ?18 improves DFS. Copyright © 2023 Ünal, Özmen, Ordu, Pilanci, İlgün, Gökmen, Almuradova, Özdoğan, Güler, Uras, Kara, Demircan, Işık, Alço, Saip, Aydın, Duymaz, Çelebi, Yararbaş, Soybir and Ozmen.en_US
dc.identifier.doi10.3389/fonc.2023.1151733
dc.identifier.issn2234-943X
dc.identifier.scopus2-s2.0-85164956724en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.3389/fonc.2023.1151733
dc.identifier.urihttps://hdl.handle.net/11454/102491
dc.identifier.volume13en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherFrontiers Media SAen_US
dc.relation.ispartofFrontiers in Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subject21 genesen_US
dc.subjectclinicopathologic characteristicsen_US
dc.subjectearly-stage breast canceren_US
dc.subjectlymph node-negativeen_US
dc.subjectOncotype DX®en_US
dc.subjectrecurrence scoreen_US
dc.titleSurvival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu